New drug duo aims to shrink aggressive breast cancer before surgery
NCT ID NCT07054242
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of two drugs—sacituzumab tirumotecan and pembrolizumab—given before surgery to people with stage II or III triple-negative breast cancer. The goal is to see if the treatment can completely eliminate the cancer by the time of surgery. The study plans to enroll 52 participants who have not had prior treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sacituzumab tirumotecan (SKB264) and pembrolizumab
- What this could lead to
- If successful, this combination could become a new pre-surgery treatment option for triple-negative breast cancer, potentially improving the chance of eliminating the tumor before surgery.
- What could go wrong
- This is a small, early-phase trial with only 52 participants. The combination may cause side effects, and it is not yet known if it works better than current standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOADJUVANT THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Breast Surgery, Yantai Yuhuangding Hospital
Yantai, Shandong, 264000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- Can a triple threat of drug, immunotherapy, and radiation wipe out High-Risk urinary tract cancer before surgery?
- Could a Triple-Drug attack before surgery eliminate more breast cancer in older women?
- Modified herpes virus joins forces with immunotherapy to attack head and neck tumors
- New targeted pill could boost lung cancer surgery success
- AI model could help doctors predict bladder cancer treatment outcomes